AbbVie Inc.
Anti-EGFR Antibody-Drug Conjugates
Last updated:
Abstract:
The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.
Status:
Application
Type:
Utility
Filling date:
20 Jan 2022
Issue date:
21 Jul 2022